Caris Life Sciences, Inc. (CAI) stock

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30121% above fair value

$23.04−0.92 (-3.84%)

Close on Nov 13, 2026Market cap $6.51BP/E –Yield –

Caris Life Sciences EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Caris Life Sciences's EV/EBITDA was 41.4× on Nov 11, 2026.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	41.4×	–

Parsed from the XBRL in Caris Life Sciences's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CAI.

Revenue growth61.5% · median 27.5%

Operating margin13.4% · median -8.2%

Net margin9.2% · median -5.9%

Advertisement
300 × 250

See a number that looks wrong?